TRIM5α restriction affects clinical outcome and disease progression in simian immunodeficiency virus-infected rhesus macaques.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 4338887)

Published in J Virol on December 03, 2014

Authors

Fan Wu1, Ilnour Ourmanov1, Nadeene Riddick1, Kenta Matsuda1, Sonya Whitted1, Ronald J Plishka1, Alicia Buckler-White1, Matthew F Starost2, Vanessa M Hirsch3

Author Affiliations

1: Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA.
2: Division of Veterinary Resources, OD, ORS, NIH, Bethesda, Maryland, USA.
3: Laboratory of Molecular Microbiology, NIAID, NIH, Bethesda, Maryland, USA vhirsch@niaid.nih.gov.

Articles cited by this

Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53

RNA-guided human genome engineering via Cas9. Science (2013) 48.29

Genome editing with engineered zinc finger nucleases. Nat Rev Genet (2010) 18.88

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature (2004) 17.56

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62

Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature (2004) 7.10

Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci U S A (2005) 6.85

TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature (2011) 6.29

A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol (2005) 5.24

Genome engineering with zinc-finger nucleases. Genetics (2011) 4.66

Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med (1997) 3.53

HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr (2007) 3.38

TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol (2010) 3.21

A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol (1997) 2.46

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med (2002) 2.36

TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys. PLoS Pathog (2010) 2.33

Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. J Virol (2006) 1.96

High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans. Curr Biol (2006) 1.85

Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A (2008) 1.83

Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J Clin Invest (2009) 1.73

Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol (2006) 1.62

Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology (2006) 1.59

APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol (2010) 1.58

Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood (2011) 1.49

Role of common human TRIM5alpha variants in HIV-1 disease progression. Retrovirology (2006) 1.46

The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog (2008) 1.41

Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol (2010) 1.15

TRIM5α does not affect simian immunodeficiency virus SIV(mac251) replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure. J Virol (2011) 1.11

Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med (2012) 1.07

Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Mol Ther (2009) 1.03

Impact of gene-modified T cells on HIV infection dynamics. J Theor Biol (2005) 1.01

Human immunodeficiency virus type 1 restriction by human-rhesus chimeric tripartite motif 5alpha (TRIM 5alpha) in CD34(+) cell-derived macrophages in vitro and in T cells in vivo in severe combined immunodeficient (SCID-hu) mice transplanted with human fetal tissue. Hum Gene Ther (2008) 1.01

Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques. J Virol (2012) 0.95

Generation of human TRIM5alpha mutants with high HIV-1 restriction activity. Gene Ther (2010) 0.95

TRIM5 alpha drives SIVsmm evolution in rhesus macaques. PLoS Pathog (2013) 0.92

Wild type and H43Y variant of human TRIM5alpha show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro. Immunogenetics (2007) 0.91

Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment. Retrovirology (2012) 0.87

Host SAMHD1 protein promotes HIV-1 recombination in macrophages. J Biol Chem (2013) 0.85

Plastic proteins and monkey blocks: how lentiviruses evolved to replicate in the presence of primate restriction factors. PLoS Pathog (2014) 0.79